- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Chelsee Jensen on the Solution to Stocking Multiple Biosimilars for the Same Reference Product
Chelsee Jensen, PharmD, pharmaceutical formulary manager at the Mayo Clinic, provides her take on why practices will have to continue to stock multiple biosimilars for the same reference product.
Chelsee Jensen, PharmD, pharmaceutical formulary manager at the Mayo Clinic, provides her take on why practices will have to continue to stock multiple biosimilars for the same reference product.
Transcript
What can practices do to help manage the possibility of having to stock and manage multiple biosimilars for the same reference product?
Jensen: Unfortunately, I do not see this going away anytime soon until we have some more of that biosimilar parity legislation or more collaboration between health systems and payers on choosing preferred products. Until then, we're going to have to stock whatever biosimilars are covered by the patient's insurance in order to prevent that patient liability.
Delgocitinib Is Redefining Chronic Hand Eczema Treatment: A Q&A With Raj Chovatiya, MD, PhD, MSCI
November 10th 2025Delgocitinib has emerged as a promising treatment for CHE, addressing unmet needs and enhancing understanding of this complex condition, notes Raj Chovatiya, MD, PhD, MSCI.
Read More
